BOSTON, August 18, 2026
Curavit Clinical Research, a next-generation clinical research organization (CRO) and Remote Clinical Site, announced the acquisition of the CRO assets of Lindus Health, expanding its clinical research capabilities into Europe. The transaction is designed to create a unified platform for decentralized, hybrid and traditional clinical trials across North America and Europe, giving pharmaceutical, biotechnology, medical technology, diagnostics and digital health sponsors access to broader clinical research services. The acquisition strengthens Curavit’s ability to support global trial execution, patient recruitment and evidence generation while addressing the increasing need for flexible and technology-enabled clinical research models.
Curavit Expands Clinical Research Across Europe
The acquisition follows Lindus Health’s decision to shift its strategic focus toward developing its own therapeutic pipeline as Lindus Therapeutics. By integrating Lindus Health’s European CRO assets and team with Curavit’s established U.S. clinical research infrastructure, the combined organization aims to provide sponsors with a single operational partner for studies conducted across multiple regions. Curavit said the expanded capabilities are intended to address challenges faced by life science companies seeking to reduce clinical trial timelines, improve patient diversity and navigate international regulatory requirements. The organization will support sponsors across pharmaceutical, biotech, MedTech, diagnostics and digital health programs, extending its ability to design and execute studies that match the requirements of emerging healthcare technologies and therapeutic programs. The expanded organization will combine full-service CRO capabilities with Remote Clinical Site operations, creating an integrated approach to prospective clinical research. Curavit specializes in decentralized and hybrid clinical trials, prospective real-world evidence studies and longitudinal participant engagement. The addition of Lindus Health’s European assets is expected to strengthen its ability to coordinate clinical studies across geographic markets while providing sponsors with a more streamlined approach to trial planning and execution. The company said the combined capabilities can support accelerated site activation, remote recruitment and fit-for-purpose study designs intended to improve operational efficiency and participant engagement.
Decentralized Trials Support Faster Patient Recruitment
A key component of Curavit’s expanded model is its focus on decentralized and hybrid clinical trials, which can incorporate remote participation alongside conventional clinical research infrastructure. These approaches are designed to reduce unnecessary travel and participation burdens while potentially improving access to studies for broader patient populations. Curavit said its Remote Clinical Site capabilities can support remote patient recruitment, participant retention and longitudinal engagement, while maintaining the clinical processes required for prospective evidence generation. The company believes these capabilities are increasingly important as life science sponsors seek more flexible ways to conduct clinical studies. Traditional clinical trial models can involve complex site networks and significant logistical requirements, particularly when studies span multiple countries. By combining technology-enabled remote services with established CRO operations, Curavit aims to offer sponsors an alternative model for conducting multi-region clinical research. The acquisition therefore expands the organization’s ability to support studies requiring both centralized clinical operations and distributed participant engagement across the United States and Europe.
Advertisement
Acquisition Strengthens Evidence Generation
The combined Curavit organization is positioned to provide services spanning clinical trial execution, prospective real-world evidence, decentralized research and hybrid study delivery. These capabilities are relevant to sponsors developing medicines, medical devices, diagnostics and digital health technologies that require high-quality clinical evidence before commercialization or broader adoption. Curavit said the acquisition will help sponsors accelerate study execution while reducing site burden and supporting participant retention. The transaction also reflects a broader transformation in the clinical research and CRO industry, where sponsors are increasingly seeking technology-enabled partners capable of delivering studies efficiently across multiple regions. By integrating European clinical research assets with its U.S. CRO and Remote Clinical Site infrastructure, Curavit aims to strengthen its position as a flexible global clinical research partner. The company expects the expanded capabilities to support faster recruitment, efficient trial operations and high-quality clinical data for life science sponsors across North America and Europe.
Source: Curavit Clinical Research press relese
